The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CR Bard's revenues will grow 1.0% and EPS will wane -14.8%.
The average estimate for revenue is $750.1 million. On the bottom line, the average EPS estimate is $1.38.
Last quarter, CR Bard reported revenue of $740.3 million. GAAP reported sales were 1.4% higher than the prior-year quarter's $730.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.44. GAAP EPS of $1.08 for Q1 were 33% lower than the prior-year quarter's $1.60 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.1%, 160 basis points worse than the prior-year quarter. Operating margin was 22.9%, 450 basis points worse than the prior-year quarter. Net margin was 12.3%, 670 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $3.06 billion. The average EPS estimate is $6.23.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 287 members out of 296 rating the stock outperform, and nine members rating it underperform. Among 113 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 113 give CR Bard a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CR Bard is hold, with an average price target of $104.75.
Is CR Bard the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add CR Bard to My Watchlist.